Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting … – Business Wire (press release)
|
Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting …
Business Wire (press release) This new license allows Immunomic to combine its investigational nucleic acid based immunotherapy platform, LAMP-Vax, with a patented and proprietary CMV immunotherapy platform, developed at Duke University by Drs. John H. Sampson and Duane A. |
